|
23/01/2012 |
MorphoSys Strengthens Patent Position on MOR202 Program |
 |
|
21/12/2011 |
MorphoSys Initiates Phase 1b Clinical Trial with MOR103 in Patients with Multiple Sclerosis |
|
|
15/12/2011 |
MorphoSys and Novozymes Sign Long-Term Alliance on Slonomics® Technology for Industrial Biotechnology Applications |
|
|
08/12/2011 |
MorphoSys to Receive Milestone Payment for CNTO 1959 Phase 2 Program |
|
|
06/12/2011 |
MorphoSys Unveils Next-Generation Antibody Technology Ylanthia® |
|
|
02/11/2011 |
MorphoSys and Shionogi Agree Three-Year Extension of Research Partnership |
|
|
28/10/2011 |
MorphoSys AG Reports Nine Months' 2011 Results |
|
|
12/10/2011 |
AbD Serotec, Moredun Research Institute and Roslin Institute Announce Grant Funding to Establish Veterinary Research Reagents |
|
|
14/09/2011 |
MorphoSys Announces Clinical Milestone in Cancer Antibody Program with Bayer HealthCare Pharmaceuticals |
|
|
01/09/2011 |
MorphoSys Doses First Patient in Phase 1/2a Clinical Trial for MOR202 Program in Multiple Myeloma |
|
|
01/08/2011 |
AbD Serotec and Merck Sign License Agreement for Use of HuCAL GOLD in Vaccine Research |
|
|
29/07/2011 |
MorphoSys AG Reports Strong Six Months 2011 Results |
|
